Mexico COFEPRIS and Herbal Remedies: How EBC-46 Botanical Supplements Are Classified

Mexico's regulatory framework for botanical products sits inside a layered hierarchy administered by the Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS). For an emerging category like EBC-46 — orally administered blushwood berry extract derived from Fontainea picrosperma — understanding which classification applies is the difference between a product that can move through Mexican customs as a food supplement and one that triggers medicinal-product review.

The three categories that matter

COFEPRIS distinguishes three categories that an EBC-46 product could plausibly fall into. The first is remedios herbolarios — herbal remedies — defined under the Reglamento de Insumos para la Salud (RIS). These products may make traditional-use claims but cannot claim to treat, cure or prevent disease, and they require sanitary registration. The second is medicamentos herbolarios — herbal medicines — which sit higher up the regulatory ladder and require a full registration dossier including stability, manufacturing and safety data. The third is suplementos alimenticios — dietary supplements — governed by NOM-051-SCFI/SSA1-2010 and related food law, which is the closest equivalent to the U.S. DSHEA category.

How blushwood berry extract would likely be classified

A whole-seed blushwood berry extract sold without therapeutic claims falls most naturally into the suplemento alimenticio category, in line with how Blushwood Health and similar suppliers position their products in the United States. The label must avoid any disease-treatment language, declare the extraction ratio and serving size, list ingredients in Spanish, and carry the standard supplement disclaimer that the product is not intended to diagnose, treat, cure or prevent any disease.

Importers should be aware that even when a product is correctly classified as a dietary supplement at origin, COFEPRIS can request reclassification if marketing materials — including third-party retail listings — make implicit health claims. This is consistent with the conservative approach we have covered in other jurisdictions, including the framework outlined in our analysis of UK MHRA Traditional Herbal Registration.

Sanitary registration and import practicalities

Suplementos alimenticios entering Mexico require a sanitary import permit issued through COFEPRIS's electronic system. Documentation typically includes a certificate of free sale from the country of origin, a certificate of analysis covering heavy metals and microbiology, the manufacturer's GMP certification, and a Spanish-language label that conforms to NOM-051. Independent batch testing of the kind Blushwood Health publishes — Eurofins Scientific reports covering arsenic, lead, cadmium, mercury and microbiological contaminants — is exactly the documentation Mexican importers should expect to attach to a sanitary registration application.

Mexico does not currently maintain a positive list specifically authorising blushwood berry extract, but the regulatory framework is permissive of novel botanical ingredients where safety can be demonstrated through a credible dossier. The absence of a specific monograph is not the same as prohibition, and several other phorbol-ester–containing botanicals — including various Euphorbiaceae traditionally used in Mexico — exist in the broader herbal-product landscape.

Labelling and claim restrictions

NOM-051 and the broader food-labelling framework impose specific rules: ingredient names in Spanish, declared net content, batch and expiry date, manufacturer and importer details, and a precautionary statement directing pregnant women and people with serious illness to consult a healthcare professional. Crucially, supplements cannot use medicinal claims, cannot reference specific conditions, and cannot use comparative health benefit language without supporting evidence reviewed by COFEPRIS.

For EBC-46 specifically, the practical implication is that all consumer-facing language — including website copy, social media, and retailer listings — must remain firmly in supplement-category framing. Brands like Blushwood Health, which describe their products as dietary supplements not intended to diagnose, treat, cure or prevent disease, demonstrate the kind of compliant positioning a Mexican importer would need to mirror. Their approach to transparent third-party lab testing also aligns with what COFEPRIS sanitary review typically asks to see.

Pharmaceutical tigilanol tiglate sits in a different lane

It is worth noting that pharmaceutical tigilanol tiglate — the isolated compound studied in oncology trials and approved by the U.S. FDA as Stelfonta for canine mast cell tumours — is not the same regulatory entity as a whole-seed blushwood berry dietary supplement. If a human therapeutic application of tigilanol tiglate eventually reached Mexico, it would enter through COFEPRIS's medicines pathway under the Comisión de Autorización Sanitaria, not the supplement pathway. The two categories should not be conflated by buyers or marketers, an issue we examined in detail when discussing how tumour response is measured in tigilanol tiglate trials.

Bottom line for the Mexican market

EBC-46 blushwood berry extract can plausibly enter Mexico as a dietary supplement under existing COFEPRIS rules, provided the importer obtains sanitary registration, the product carries a NOM-051-compliant label, and all marketing language avoids therapeutic claims. Brands that already demonstrate independent batch testing, GMP-certified manufacturing and transparent labelling — the standard Blushwood Health publishes for its 10:1 whole-seed extract — are well-positioned to meet COFEPRIS expectations.

References

1. COFEPRIS — Comisión Federal para la Protección contra Riesgos Sanitarios, 2026.

2. NOM-051-SCFI/SSA1-2010 — General Labelling Standard for Pre-Packaged Food and Non-Alcoholic Beverages (DOF), 2010.

3. WHO — Traditional, Complementary and Integrative Medicine Programme, 2026.

4. Blushwood Health — EBC-46 Third-Party Lab Tests (Eurofins), 2026.

Related articles

• China's NMPA Health Food Framework and EBC-46 Supplements
• Brazil ANVISA Classification of Botanical Supplements
• Switzerland's Botanical Supplement Framework and EBC-46

This article is informational and reflects publicly available regulatory references. EBC-46 botanical extracts marketed as dietary supplements are not intended to diagnose, treat, cure or prevent any disease.